Developer docs
API playgroundTry for free, no card

Search company profiles

Epalex

Full company profile

uuid0002xu3

Namestring
Epalex
Legal namestring
Epalex Corp
Websiteurl
epalex.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Epalex Corp is a privately held, clinical-stage pharmaceutical company incorporated in Delaware and headquartered in Mountain View, California. The company is developing two oral small-molecule drug candidates targeting large unmet needs in neurology: EP102 for the acute treatment of migraine, and EP103 for drug-refractory epilepsy. Both candidates are formulated using Epalex's proprietary, patent-pending oral drug delivery technology, which is designed to substantially increase peak plasma concentration (Cmax) and area under the curve (AUC) relative to standard tablet formulations, enabling oral administration of active pharmaceutical ingredients that were previously only deliverable via intravenous infusion. EP102's mechanism modulates GABAergic inhibition at GABAA receptors and may inhibit cortical spreading depression, positioning it as differentiated from NSAIDs, triptans, ergots, and CGRP antagonists. EP103 is a broad-spectrum antiseizure agent with a non-benzodiazepine mechanism, demonstrated in preclinical PTZ-induced seizure models to delay seizure onset up to four-fold versus control (p<0.001).

Epalex has completed a Phase 1a single-ascending-dose study in 99 healthy adults for EP102, establishing a well-characterized pharmacokinetic and safety/tolerability profile, and a proof-of-concept study is currently underway. EP103 remains pre-IND with preclinical efficacy data only. The company is pre-revenue with no commercial products, no pricing, and no distribution channels; future revenue is contingent on FDA approval and either direct commercialization or out-licensing of EP102 and EP103. Capital to date has been raised exclusively through SEC Form D exempt securities offerings totaling roughly $30.8M across 2017, 2018, 2022, 2024, and 2025, with no disclosed institutional lead investors or strategic pharma partner. The leadership team is concentrated in CNS drug development, with senior executives drawn from Bayer, Teva, Novartis, Boehringer Ingelheim, Abbott, Eagle Pharmaceuticals, and URL Pharma, supported by academic founders from NINDS and UC Davis.

The business model is a traditional clinical-development-and-exit pathway: advance EP102 and EP103 through Phase 2/3 trials, then either commercialize (likely specialty neurology sales force into migraine and refractory epilepsy channels) or partner/out-license to a larger pharmaceutical company. The target patient populations are substantial — approximately 38 million U.S. adults with migraine (fewer than half adequately controlled by current therapies) and 3 million U.S. adults plus 470,000 children with active epilepsy (only ~50% achieving adequate seizure control on existing medications, with 20-30% drug-refractory) — but Epalex has not yet entered human pivotal trials and remains several years and several hundred million dollars of capital away from any product launch.

Short descriptiontext

Epalex Corp is a privately held, clinical-stage pharmaceutical company developing EP102, an oral migraine therapy, and EP103, an oral non-benzodiazepine epilepsy therapy, both enabled by a proprietary oral drug delivery platform that improves bioavailability of drugs previously requiring IV administration.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
acute migraine therapy, antiseizure medication, oral drug delivery, epilepsy treatment, clinical-stage pharmaceuticals
Industry1 code
PRIMARYHLACAKAJ
Controlled Substance ePrescribing (EPCS), Diversion Monitoring & Compliance
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neurology Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage company. Revenue will be generated through sales of EP102 (migraine) and EP103 (epilepsy) upon successful FDA approval and commercialization.

epalex.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Epalex is a clinical-stage pharmaceutical company developing two core drug candidates: EP102, an oral therapy for acute migraine treatment, and EP103, an oral broad-spectrum antiseizure agent for drug-refractory epilepsy. Both candidates leverage the company's proprietary, patent-pending oral delivery technology that substantially increases bioavailability compared to standard tablet formulations, enabling oral administration of drug substances previously only available intravenously.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • EP103 displayed a dose-related delay (up to four-fold) in seizure onset in PTZ-induced seizure model in rats, statistically significant (p<0.001, 2-tailed)
+2 more records
Product overview1 text field

Epalex is a clinical-stage pharmaceutical company developing a portfolio of breakthrough therapies for migraine and epilepsy. The company's product pipeline centers on two core drug candidates: EP102 for acute migraine treatment and EP103 for drug-refractory epilepsy. Both products leverage Epalex's proprietary, patent-pending oral delivery technology that improves bioavailability by substantially increasing Cmax and AUC compared to standard tablets. This delivery technology enables oral administration of drugs previously only available intravenously in emergency or inpatient settings.

Product and service1 record
1EP102
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage CNS pharmaceutical company focused on epilepsy and seizure disorders, including drug-resistant forms. Co-founded by Epalex co-founder Randall Murphy, making it a particularly direct comparable in indication, stage, and therapeutic approach.

TypeDirect peer
Description

Specialty pharmaceutical company developing and commercializing treatments for epilepsy and central nervous system disorders, including the marketed antiseizure Xcopri. Directly comparable to Epalex's EP103 as a CNS-focused epilepsy developer with late-stage clinical assets.

TypeDirect peer
Description

Clinical-stage CNS biopharmaceutical company developing therapies for migraine and other neurological conditions. Comparable to Epalex as a similarly-sized, CNS-focused developer pursuing differentiated mechanisms in migraine and related indications.

TypeBroad incumbent
Description

Global biopharmaceutical company with a major neurology franchise including marketed antiseizure drugs (Keppra, Briviact, Vimpat). Comparable to Epalex in target indication (epilepsy) but as a large, diversified incumbent with established commercial infrastructure.

TypeBroad incumbent
Description

Global pharmaceutical company with a focused CNS and migraine franchise including Vyepti (anti-CGRP) and several migraine therapies. Comparable to Epalex in target indications (migraine and CNS) but as a large established incumbent.

TypeBroad incumbent
Description

Global pharmaceutical company with a major migraine franchise acquired via Biohaven Pharmaceuticals (Nurtec ODT, Zavzpret). Comparable to Epalex as a key migraine competitor but with vastly larger commercial resources and an established CGRP portfolio.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company focused on neurological and CNS disorders, including rare epilepsies. Comparable to Epalex as a similarly-staged, smaller CNS developer targeting seizure disorders with differentiated mechanisms.

TypeEmerging player
Description

Clinical-stage neuroscience company developing therapies for epilepsy, depression, and other CNS conditions. Comparable to Epalex in stage, indication overlap (epilepsy), and approach of pursuing differentiated CNS mechanisms.

9Eliem Therapeutics
TypeEmerging player
Description

Clinical-stage biotechnology company focused on central nervous system disorders including epilepsy and depression. Comparable to Epalex as a small-cap CNS developer pursuing differentiated mechanisms in neurology indications.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing precision medicines for CNS disorders including depression and other neurological conditions. Comparable to Epalex as a well-funded CNS developer with multiple clinical-stage neurology programs.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Epalex

Neurology Pharmaceuticalsepalex.com

Epalex Corp is a privately held, clinical-stage pharmaceutical company developing EP102, an oral migraine therapy, and EP103, an oral non-benzodiazepine epilepsy therapy, both enabled by a proprietary oral drug delivery platform that improves bioavailability of drugs previously requiring IV administration.

What Epalex does

Epalex Corp is a privately held, clinical-stage pharmaceutical company incorporated in Delaware and headquartered in Mountain View, California. The company is developing two oral small-molecule drug candidates targeting large unmet needs in neurology: EP102 for the acute treatment of migraine, and EP103 for drug-refractory epilepsy. Both candidates are formulated using Epalex's proprietary, patent-pending oral drug delivery technology, which is designed to substantially increase peak plasma concentration (Cmax) and area under the curve (AUC) relative to standard tablet formulations, enabling oral administration of active pharmaceutical ingredients that were previously only deliverable via intravenous infusion. EP102's mechanism modulates GABAergic inhibition at GABAA receptors and may inhibit cortical spreading depression, positioning it as differentiated from NSAIDs, triptans, ergots, and CGRP antagonists. EP103 is a broad-spectrum antiseizure agent with a non-benzodiazepine mechanism, demonstrated in preclinical PTZ-induced seizure models to delay seizure onset up to four-fold versus control (p<0.001).

Epalex has completed a Phase 1a single-ascending-dose study in 99 healthy adults for EP102, establishing a well-characterized pharmacokinetic and safety/tolerability profile, and a proof-of-concept study is currently underway. EP103 remains pre-IND with preclinical efficacy data only. The company is pre-revenue with no commercial products, no pricing, and no distribution channels; future revenue is contingent on FDA approval and either direct commercialization or out-licensing of EP102 and EP103. Capital to date has been raised exclusively through SEC Form D exempt securities offerings totaling roughly $30.8M across 2017, 2018, 2022, 2024, and 2025, with no disclosed institutional lead investors or strategic pharma partner. The leadership team is concentrated in CNS drug development, with senior executives drawn from Bayer, Teva, Novartis, Boehringer Ingelheim, Abbott, Eagle Pharmaceuticals, and URL Pharma, supported by academic founders from NINDS and UC Davis.

The business model is a traditional clinical-development-and-exit pathway: advance EP102 and EP103 through Phase 2/3 trials, then either commercialize (likely specialty neurology sales force into migraine and refractory epilepsy channels) or partner/out-license to a larger pharmaceutical company. The target patient populations are substantial — approximately 38 million U.S. adults with migraine (fewer than half adequately controlled by current therapies) and 3 million U.S. adults plus 470,000 children with active epilepsy (only ~50% achieving adequate seizure control on existing medications, with 20-30% drug-refractory) — but Epalex has not yet entered human pivotal trials and remains several years and several hundred million dollars of capital away from any product launch.

Epalex firmographics

Firmographics
Name
Epalex
Legal name
Epalex Corp
Website
https://epalex.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
Epalex Corp is a privately held, clinical-stage pharmaceutical company developing EP102, an oral migraine therapy, and EP103, an oral non-benzodiazepine epilepsy therapy, both enabled by a proprietary oral drug delivery platform that improves bioavailability of drugs previously requiring IV administration.
Ownership category
akta.pro rank

Epalex industry classification

Industry
Product category
Neurology Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACAKAJ
Controlled Substance ePrescribing (EPCS), Diversion Monitoring & Compliance
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT

Keywords

  • Acute migraine therapy
  • Antiseizure medication
  • Oral drug delivery
  • Epilepsy treatment
  • Clinical-stage pharmaceuticals

Where Epalex is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Epalex business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Revenue will be generated through sales of EP102 (migraine) and EP103 (epilepsy) upon successful FDA approval and commercialization.

Go-to-market motion1 record

Marketing channels1 record

Epalex product offering

Product offering

Core offering

Epalex is a clinical-stage pharmaceutical company developing two core drug candidates: EP102, an oral therapy for acute migraine treatment, and EP103, an oral broad-spectrum antiseizure agent for drug-refractory epilepsy. Both candidates leverage the company's proprietary, patent-pending oral delivery technology that substantially increases bioavailability compared to standard tablet formulations, enabling oral administration of drug substances previously only available intravenously.

Product overview

Epalex is a clinical-stage pharmaceutical company developing a portfolio of breakthrough therapies for migraine and epilepsy. The company's product pipeline centers on two core drug candidates: EP102 for acute migraine treatment and EP103 for drug-refractory epilepsy. Both products leverage Epalex's proprietary, patent-pending oral delivery technology that improves bioavailability by substantially increasing Cmax and AUC compared to standard tablets. This delivery technology enables oral administration of drugs previously only available intravenously in emergency or inpatient settings.

Differentiator

Problem solved

Functional benefit

Products and services

  • EP102

Quantifiable outcome

  • EP103 displayed a dose-related delay (up to four-fold) in seizure onset in PTZ-induced seizure model in rats, statistically significant (p<0.001, 2-tailed)
  • +2 more outcomes

Companies that use Epalex

Customer profile

Segments2 records

Ideal customer profiles2 records

Epalex technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Epalex partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Epalex competitors and assessment

Company assessment

Direct peers

  • Marinus Pharmaceuticals: Clinical-stage CNS pharmaceutical company focused on epilepsy and seizure disorders, including drug-resistant forms. Co-founded by Epalex co-founder Randall Murphy, making it a particularly direct comparable in indication, stage, and therapeutic approach.
  • SK Life Science: Specialty pharmaceutical company developing and commercializing treatments for epilepsy and central nervous system disorders, including the marketed antiseizure Xcopri. Directly comparable to Epalex's EP103 as a CNS-focused epilepsy developer with late-stage clinical assets.
  • Axsome Therapeutics: Clinical-stage CNS biopharmaceutical company developing therapies for migraine and other neurological conditions. Comparable to Epalex as a similarly-sized, CNS-focused developer pursuing differentiated mechanisms in migraine and related indications.

Broad incumbents

  • UCB: Global biopharmaceutical company with a major neurology franchise including marketed antiseizure drugs (Keppra, Briviact, Vimpat). Comparable to Epalex in target indication (epilepsy) but as a large, diversified incumbent with established commercial infrastructure.
  • Lundbeck: Global pharmaceutical company with a focused CNS and migraine franchise including Vyepti (anti-CGRP) and several migraine therapies. Comparable to Epalex in target indications (migraine and CNS) but as a large established incumbent.
  • Pfizer: Global pharmaceutical company with a major migraine franchise acquired via Biohaven Pharmaceuticals (Nurtec ODT, Zavzpret). Comparable to Epalex as a key migraine competitor but with vastly larger commercial resources and an established CGRP portfolio.

Emerging players

  • Longboard Pharmaceuticals: Clinical-stage biopharmaceutical company focused on neurological and CNS disorders, including rare epilepsies. Comparable to Epalex as a similarly-staged, smaller CNS developer targeting seizure disorders with differentiated mechanisms.
  • Engrail Therapeutics: Clinical-stage neuroscience company developing therapies for epilepsy, depression, and other CNS conditions. Comparable to Epalex in stage, indication overlap (epilepsy), and approach of pursuing differentiated CNS mechanisms.
  • Eliem Therapeutics: Clinical-stage biotechnology company focused on central nervous system disorders including epilepsy and depression. Comparable to Epalex as a small-cap CNS developer pursuing differentiated mechanisms in neurology indications.
  • Neumora Therapeutics: Clinical-stage biopharmaceutical company developing precision medicines for CNS disorders including depression and other neurological conditions. Comparable to Epalex as a well-funded CNS developer with multiple clinical-stage neurology programs.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Epalex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Epalex leadership team

Management profile

Number of profiles

Profiles7 records

Epalex funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Epalex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epalex

What does Epalex do?

Epalex is a clinical-stage pharmaceutical company developing two core drug candidates: EP102, an oral therapy for acute migraine treatment, and EP103, an oral broad-spectrum antiseizure agent for drug-refractory epilepsy. Both candidates leverage the company's proprietary, patent-pending oral delivery technology that substantially increases bioavailability compared to standard tablet formulations, enabling oral administration of drug substances previously only available intravenously.

Is Epalex a public or private company?

Epalex is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Epalex founded?

Epalex was founded in 2009. It employs 1 to 10 people.

Where is Epalex based?

Epalex is headquartered in Palo Alto, United States, in the North America region.

How does Epalex make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Epalex's main competitors?

Direct peers on record are Marinus Pharmaceuticals, SK Life Science and Axsome Therapeutics. Broad incumbents are UCB, Lundbeck and Pfizer. Emerging players are Longboard Pharmaceuticals, Engrail Therapeutics, Eliem Therapeutics and Neumora Therapeutics.

Does Epalex have an API?

No public API is recorded for Epalex.

What industry is Epalex in?

Epalex's product category is Neurology Pharmaceuticals. Its primary akta.pro industry code is HLACAKAJ, Controlled Substance ePrescribing (EPCS), Diversion Monitoring & Compliance. Its NAICS code is 3254 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals